Dr. Guiling Li 李贵玲
Chief Physician, Associate Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and radiotherapy for lung, gynecologic, and urogenital tumors. Intracavitary brachytherapy for cervical, nasopharyngeal, esophageal, and bile duct cancers.
Dr. Li is Deputy Director of the Cancer Center at Union Hospital. The doctor focuses on comprehensive treatment of cervical, ovarian, and endometrial cancers, including radiotherapy, chemotherapy, targeted therapy, immunotherapy, and interstitial brachytherapy. Dr. Li has led or participated in multiple clinical studies, including one National High-Tech Research and Development Program (863 Program) project.
Professional roles
- Member, Gynecologic Oncology Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Brachytherapy Committee, Chinese Medical Doctor Association
- Vice Chair, Gynecologic Oncology Committee, Hubei Anti-Cancer Association
- Standing Committee Member, Radiotherapy Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Guiling). Papers usually list the name as Guiling Li or Li G.
Selected publications
70 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Rep, 2026 (senior author): [Retracted] MicroRNA‑18a enhances the radiosensitivity of cervical cancer cells by promoting radiation‑induced apoptosis. PubMed 41268606
- Front Immunol, 2025 (senior author): Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer. PubMed 41438759
- Gynecol Oncol, 2024 (first author): Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. PubMed 39447517
- Onco Targets Ther, 2023 (first author): Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. PubMed 36911534
- Med Oncol, 2022 (senior author): CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer. PubMed 36567417
- Ir J Med Sci, 2022 (senior author): Duration of antibody responses following severe acute respiratory syndrome coronavirus 2 infection. PubMed 34982375
- Front Immunol, 2022 (senior author): Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. PubMed 36275726
- Front Oncol, 2022 (first author): Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type. PubMed 35903699
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion